Medical data are usually stored in what known as electronic health records (EHRs) where patients’ demographics, conditions, treatments and progress are systematically tracked. In US, an estimated 85% of general practitioners and over 90% of hospitals are relying on EHRs.
However, according to Health Information & The Law, a collaborative project between George Washington University and Robert Wood Johnson Foundation, most states in US do not have law to confer specific ownership of medical data to patients, while others put the rights on hospitals and physicians. Of all, only New Hampshire allows patients to legally own their medical records.
Across the Atlantic, under the new General Data Protection Regulation (GDPR) implemented on all European Union countries this May, healthcare providers do not have to seek prior permission from patients to use their data, as long as they observe the professional secrecy act to not identify patient at individual level.
Although we don’t have an absolute say on our medical records like the way we do for cookies, data has been playing a rather crucial role in the growing AI med industry. UK’s National Health Service tends to go paperless by 2020, replacing it with a decision support system to comprehend large amount of data at one go, enabling a more personalized treatment solely based on a patient’s medical history.
Furthermore, patients’ data are effective curriculum for AI based systems to make prognosis or suggestive treatments to patients, in the case when there is a shortage in healthcare providers. The McKinsey Global Institute believes instilling big data strategies into medical decision making can generate up to US$100 billion annual revenue in the US healthcare system.
As data breach remains the biggest threat to eHealth, a group AI med experts are gathering to discuss the potential of medical data, privacy and related risk factors.
Session Focus: Medical Data: Who owns the data and what can be done to it
When: Thursday, November 8th (16.00-17.00)
Listen to experts from US, UK, Middle East and Asia, on the advantages, impacts and liability of using patients’ medical data in diagnosis and treatments.
Attendees will gain the following knowledge:
Learn the trends of eHealth; how healthcare institutions are making use of patients’ data now and near future and what else can be done.
Understand the advantages and risks of employing medical data and how each of them affects the development of AI med industry in general.
Review data policies across different countries and how patients can have a better control of their own medical records while not restrains the development of AI med at the same time.
Benefit from experts’ opinions and a chance to mingle with professionals with similar interests.
Steve Roesing, CEO, ASMGi, USA
Harpreet Sood, Associate Chief Clinical Information Officer, NHS England, UK
Walid Abbas Zaher, Group Clinical Research & Development Director and Vice-chairman of research and development oversight committee, Abu Dhabi Health Services Company (SEHA), UAE
Bella Zaghi, President, HIMSS Southern California, USA
Raghu Gullapalli, Executive Director, LV Prasad Eye Institute, India
Download the full agenda for AIMed Asia here.